052260 — Hyundai BioLand Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩134bn
- KR₩144bn
- KR₩102bn
- 44
- 43
- 39
- 34
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 106,311 | 88,899 | 102,802 | 99,154 | 101,691 |
Cost of Revenue | |||||
Gross Profit | 39,278 | 17,298 | 37,291 | 35,650 | 36,726 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 92,230 | 105,823 | 116,447 | 91,775 | 93,091 |
Operating Profit | 14,081 | -16,924 | -13,645 | 7,378 | 8,599 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 12,995 | -17,921 | -15,165 | 6,844 | 9,992 |
Provision for Income Taxes | |||||
Net Income After Taxes | 10,849 | -13,545 | -11,686 | 4,764 | 8,056 |
Net Income Before Extraordinary Items | |||||
Net Income | 10,849 | -13,545 | -11,686 | 4,764 | 8,056 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 10,849 | -13,545 | -11,686 | 4,764 | 8,056 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 733 | -581 | 306 | 388 | 346 |
Dividends per Share |